Valion Bio Sets 1-for-25 Reverse Split Effective August 31 to Regain Nasdaq Compliance
VBIO sits 19% above its 52-week low of $0.112.
Summary
Valion Bio approved a 1-for-25 reverse stock split effective August 31, 2026, to regain Nasdaq's $1.00 minimum bid price compliance before the September 15 deadline.
Key Events · Corporate Governance and Compliance · VBIO
-
1-for-25 Reverse Split Approved
Board approved a 1-for-25 reverse stock split of common stock, effective August 31, 2026 at 12:01 a.m. Eastern Time.
-
Nasdaq Compliance Deadline
Company must regain compliance with Nasdaq's $1.00 minimum bid price rule by September 15, 2026; the reverse split is intended to achieve this.
-
Shareholder Approval Preceded
Stockholders approved the reverse split at a special meeting on August 14, 2026, with a previously authorized ratio range of 1-for-5 to 1-for-50.
-
New CUSIP and Trading Details
New CUSIP number 918942202 will apply; trading symbol VBIO remains unchanged; fractional shares rounded up to whole shares.
Analysis · VBIO · Life Sciences
Valion Bio's board finalized a 1-for-25 reverse stock split, effective August 31, 2026, to lift the stock price above Nasdaq's $1.00 minimum bid requirement. The company has until September 15, 2026 to regain compliance, and this split is the primary mechanism to avoid delisting. With cash at $2.1M and a going concern warning, maintaining the Nasdaq listing is critical for continued access to capital markets.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30.2% of the 2009 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.11%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $0.13 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.5M. The 52-week trading range was $0.11 to $3.21. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.